| Abstract | In this review, the clinical pharmacology of high-dose doxorubicin is examined, and the pharmacokinetics of infusional doxorubicin at standard and high dose are compared. The data developed here, including recent clinical trials of high-dose infusional doxorubicin, demonstrate the safety and efficacy of doxorubicin administration at doses > or = 150 mg/m2 for patients with breast cancer and strongly suggest that the utility of this drug can be substantially increased with appropriate hematopoietic support. |
| Authors | T W Synold, J H Doroshow
(Affiliation: Department of Medical Oncology and Therapeutics Research, City of Hope Cancer Research Center, Duarte, CA 91010, USA.)
|
| Journal | The Journal of infusional chemotherapy
(J Infus Chemother)
Vol. 6
Issue 2
Pg. 69-73
( 1996)
ISSN: 1060-0051 UNITED STATES |
| PMID | 8809652
(Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S., Review)
|
| Chemical References |
- Antibiotics, Antineoplastic
- Doxorubicin
|
| Topics |
- Antibiotics, Antineoplastic
(administration & dosage, pharmacokinetics)
- Clinical Trials as Topic
- Dose-Response Relationship, Drug
- Doxorubicin
(administration & dosage, pharmacokinetics)
- Drug Administration Schedule
- Humans
- Infusions, Intravenous
- Neoplasms
(drug therapy)
|
